Smithkline Beecham Corporation

Human Genome Sciences, Inc.

Beth Israel Deaconess Medical Center, Inc.

Jonathan Alexander Terrett

Gregg A Hastings

Zdenka Ludmila Jonak

Tania Tamson Testa

Israel Simon Gloger

Stephen H Trulli

Neil Upton

James A Fornwald

Guy Anthony Kennett

Trudy Rachel Doe

Martin Ian Smith

David Piper

James Joseph Hagan

Saraswati R Patel

Stephen A Hughes

The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.

METH1 polynucleotides

Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.

Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72

Tubby 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Tubby 2 polypeptides and polynucleotides in the design of protocols for the treatment of diabetes, obesity, and atherosclerosis, among others, and diagnostic assays for such conditions.

Tubby 2 polypeptides

Growing community of inventors

Chelmsford, United Kingdom

Jonathan Alexander Terrett